Glucagon-like peptide-1 (GLP-1), a gut-derived peptide hormone, was fist found to promote insulin release by targeting the pancreatic β cells and rapidly developed as a promising drug for the treatment of obesity and type 2 diabetes mellitus (T2DM), well-known risk factors of cardiovascular diseases [16]. Here, INS is linked to type 2 diabetes mellitus.